Therapy
Biotechnology
Medical

Adaptimmune Therapeutics

$3.67
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-0.54%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ADAP and other stocks, options, ETFs, and crypto commission-free!

About

Adaptimmune Therapeutics plc American Depositary Shares, also called Adaptimmune Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Read More The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Employees
430
Headquarters
Abingdon, Oxfordshire
Founded
2014
Market Cap
384.31M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
444.86K
High Today
$3.75
Low Today
$3.62
Open Price
$3.70
Volume
117.93K
52 Week High
$14.54
52 Week Low
$3.55

Collections

Therapy
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Cancer Prevention
Health
Technology

News

Seeking AlphaMay 15

Adaptimmune teams up with Alpine to develop next-gen cell therapies

Adaptimmune (ADAP +3.7% ) will collaborate with Alpine Immune Sciences (ALPN +4.4% ) to develop next-generation SPEAR T-cell products based on the latter's secreted and transmembrane immunomodulatory protein (SIP and TIP) technology.

129
Yahoo FinanceMay 9

Here’s What Hedge Funds Think About Adaptimmune Therapeutics plc

"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from peak to trough.

129
Associated PressMay 6

Adaptimmune Reports First Quarter 2019 Financial Results

327

Earnings

-$0.32
-$0.21
-$0.10
$0.01
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.31 per share
Actual
-$0.04 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.